Sutro Biopharma (STRO) Income from Non-Controlling Interests (2019 - 2025)
Sutro Biopharma (STRO) reported Income from Non-Controlling Interests of -$4000.0 for Q2 2025, up 97.01% sequentially from -$134000.0 in Q1 2024.
Sutro Biopharma (STRO) Income from Non-Controlling Interests (2019 - 2025) Analysis & Trends
Sutro Biopharma (STRO) has 7 years of Income from Non-Controlling Interests data on file, last reported at -$4000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Sutro Biopharma | 192.86 Mn | 51.43 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -4,000.00 |
| Mar 31, 2024 | -134,000.00 |
| Jun 30, 2023 | 123,000.00 |
| Mar 31, 2023 | 511,000.00 |
| Jun 30, 2022 | -204,000.00 |
| Mar 31, 2022 | -838,000.00 |
| Jun 30, 2021 | -45,000.00 |
| Mar 31, 2021 | -129,000.00 |
| Jun 30, 2020 | 370,000.00 |
| Mar 31, 2020 | -137,000.00 |
| Jun 30, 2019 | 157,000.00 |
| Mar 31, 2019 | 103,000.00 |